Raptor Pharmaceutical Corp. (NASDAQ:RPTP) saw an uptick in trading volume on Tuesday . 3,425,435 shares traded hands during trading, an increase of 79% from the previous session’s volume of 1,918,258 shares.The stock last traded at $7.67 and had previously closed at $7.54.

A number of brokerages have weighed in on RPTP. FBR & Co reiterated a “hold” rating and set a $10.00 target price on shares of Raptor Pharmaceutical Corp. in a research note on Tuesday, August 23rd. Cowen and Company restated a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday, August 19th. Zacks Investment Research upgraded Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Thursday, August 11th. Citigroup Inc. lowered Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $6.00 to $8.00 in a research note on Monday, August 8th. Finally, Wedbush restated a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research note on Friday, May 6th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $7.79.

The stock’s market capitalization is $654.30 million. The firm has a 50-day moving average of $6.50 and a 200 day moving average of $5.27.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last announced its earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The firm earned $32.05 million during the quarter, compared to analyst estimates of $28.52 million. During the same quarter last year, the business earned ($0.17) earnings per share. Raptor Pharmaceutical Corp.’s revenue was up 37.4% on a year-over-year basis. On average, analysts expect that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Schwab Charles Investment Management Inc. increased its stake in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 3.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,620 shares of the company’s stock after buying an additional 9,354 shares during the period. Schwab Charles Investment Management Inc. owned about 0.34% of Raptor Pharmaceutical Corp. worth $1,522,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.